The Food and Drug Administrations new acting chief has moved swiftly to reassure pro-life leaders that a long-delayed safety review of the abortion pill will finally be treated as a top priority under President Trumps second administration.
Kyle Diamantas, the FDAs deputy commissioner for food now serving as acting commissioner after the departure of Dr. Marty Makary, has signaled a sharp course correction at an agency many conservatives view with deep suspicion. According to WND, Diamantas has privately pledged to pro-life advocates that he will be the most pro-life FDA commissioner that the FDA has ever had, a striking commitment for a regulator long criticized for its permissive stance toward chemical abortion.
Within hours of his appointment, Diamantas personally reached out to leading pro-life figures, including Live Action President Lila Rose, Students for Life President Kristan Hawkins, and March for Life President Jennie Lichter. His rapid engagement stands in stark contrast to Makarys tenure, which drew intense criticism from conservatives who accused him of slow-walking a promised safety review of the abortion pill mifepristone and shrouding the process in secrecy.
Makary, together with Health and Human Services Secretary Robert F. Kennedy Jr., had earlier vowed to examine the safety of mifepristone after a study from the Ethics and Public Policy Center found that 11% of women experience adverse effects after taking the abortion pill regimen. For many in the pro-life movement, the failure to move decisively on that dataand to be transparent about itwas unacceptable, prompting widespread calls for Makarys removal.
Hawkins told The Daily Signal that Diamantas has already acknowledged the FDAs shortcomings on transparency regarding the abortion pill review. She said he indicated the agency would soon provide the pro-life movement with more detailed information about the status and substance of that review, a step long demanded by conservatives who argue women have been misled about the risks.
Rose likewise reported that Diamantas assured her that reviewing the abortion pill is a top priority for him and the administration, signaling that chemical abortion will no longer be treated as a political third rail inside the agency. That assurance is especially significant as President Trump is expected to soon name a permanent commissioner, raising the stakes for how the FDA will handle abortion policy going forward.
Almost immediately after Diamantas promotion became public, some pro-life advocates raised alarms over his past legal work representing Planned Parenthood of Greater Orlando in a single case as a young attorney. Diamantas, according to Rose, addressed the concern directly and expressed remorse for that representation.
He shared that he was assigned to the case by his law firm, performed work on it, and ultimately regretted his involvement because of his moral opposition to abortion, Rose wrote. He then asked his superiors to remove him from the case. He said that he is pro-life and cares deeply about the pro-life cause.
Lichter has said she is cautiously optimistic that Diamantas will treat the mifepristone safety evidence with the seriousness it deserves, rather than bowing to pressure from the abortion lobby. @US_FDA, looking forward to working with you in this new era to make sure abortion drug companies cant continue to lie to women about their drugs that are NOT safer than Tylenol and that abusive men are stopped from ordering these dangerous drugs on the internet and force-feeding them to pregnant women, Lichter said.
For conservatives who have long argued that unelected bureaucrats shield abortion providers from accountability, Diamantas early outreach and explicit pro-life stance suggest a potential turning point at the FDA. Whether his promises translate into concrete regulatory actionfull transparency, rigorous safety standards, and real limits on abortion pill distributionwill determine if this new era is more than rhetoric and finally puts womens health and unborn life ahead of the abortion industrys interests.
Login